References
- AVENOSO, A., SPINA, E., CAMPO, G., FACCIOLA, G., FERLITO, M., ZUCCARO, P., PERUCCA, E. and CAPUTI, A. P., 1997, Interaction between fluoxetine and haloperidol — pharmacokinetic and clinical implications. Pharmacological Research, 35, 335–339.
- BAST, A. and NOORDHOEK, J., 1982, Spectral interaction of orphenadrine and its metabolites with oxidized and reduced hepatic microsomal cytochrome P-450 in the rat. Biochemical Pharmacology, 31, 2745–2753.
- BAUMANN, P., 1996, Pharmacokinetic—pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clinical Pharmacokinetics, 31, 444–469.
- BENSOUSSAN, C., DELAFORGE, M. and MANSUY, D., 1995, Particular ability of cytochromes CYP 3A to form inhibitory CYP—iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochemical Pharmacology, 49, 591–602.
- BERGSTROM, R. F., GOLDBERG, M. J., CERIMELE, B. J. and HATCHER, B. L., 1997, Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clinical Pharmacology and Therapeutics, 62, 643–651.
- CACCIA, S., 1998, Metabolism of the newer antidepressants — an overview of the pharmacological and pharmacokinetic implications. Clinical Pharmacokinetics, 34, 281–302.
- DANIEL, W. A., HADUCH, A. and WOJCIKOWSKI, J., 2002, Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. Journal of Pharmacy and Pharmacology, 54, 1545–1552.
- DELAFORGE, M., JAOUEN, M. and MANSUY, D., 1983, Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite-complexes: a structure—activity relationship. Biochemical Pharmacology, 32, 2309–2318.
- FJORDSIDE, L., JEPPESEN, U., EAP, C. B., POWELL, K., BAUMANN, P. and BROSEN, K., 1999, The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics, 9, 55–60.
- FRANKLIN, M. R., 1995, Enhanced rates of cytochrome P450 metabolic-intermediate complex formation from nonmacrolide amines in rifampicin-treated rabbit liver microsomes. Drug Metabolism and Disposition, 23, 1379–1382.
- HANSCH, C., LEO, A., UNGER, S. H., KIM, H. K., NIKAITANI, D. and LIEN, E. J., 1973, 'Aromatic' substituent constants for structure—activity correlations. Journal of Medicinal Chemistry, 16, 1207–1216.
- HANSCH, C., ROCKWELL, S. D., Jow, P. Y. C., LEO, A. and STELLER, E. E., 1977, Substituent constants for correlation analysis. Journal of Medicinal Chemistry, 20, 304–306.
- HARVEY, A. T. and PRESKORN, S. H., 2001, Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. Journal of Clinical Psychopharmacology, 21, 161–166.
- HEMERYCK, A., DE VRIENDT, C. and BELPAIRE, F. M., 1999, Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. European Journal of Clinical Pharmacology, 54, 947–951.
- JEFCOATE, C. R., 1978, Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical difference spectroscopy. Methods in Enzymology, 52, 258–279.
- JoNssoN, K.-L. and LINDEKE, B., 1992, Cytochrome P-455 nm complex formation in the metabolism of phenylalkylamines. XII. Enantioselectivity and temperature dependence in microsomes and reconstituted cytochrome P-450 systems from rat liver. Chirality, 4, 469–477.
- JONES, D. R., GORSKI, C. J. C., HAMMAN, M. A., MAYHEW, B. S., RIDER, S. and HALL, S. D., 1999, Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. Journal of Pharmacology and Experimental Therapeutics, 290, 1116–1125.
- KOBAYASHI, K., YAMAMOTO, T., CHIBA, K., TANI, M., ISHIZAKI, T. and KUROIWA, Y., 1995, The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes. British Journal of Clinical Pharmacology, 40, 481–485.
- LINDEKE, B., PAULSEN, U. and ANDERSON, E., 1979, Cytochrome P-455 complex formation in the metabolism of phenylalkylamines — IV. Spectral evidences for metabolic conversion of methamphetamine to N-hydroxyamphetamine. Biochemical Pharmacology, 28, 3629–3635.
- LOWRY, 0. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
- MANSUY, D., ROUER, E., BACOT, C., GANS, P., CHOTTARD, J. C. and LEROUX, J. P., 1978, Interaction of aliphatic N-hydroxylamines with microsomal cytochrome P450: nature of the different derived complexes and inhibitory effects on monoxygenases activities. Biochemical Pharmacology, 27, 1229–1237.
- MARCUS, C. B., WILSON, N. M., JEFCOATE, C. R., WILKINSON, C. F. and OMIECINSKI, C. J., 1990, Selective induction of cytochrome P450 isozymes in rat liver by 4-n-alkyl-methylenedi-oxybenzenes. Archives of Biochemistry and Biophysics, 277, 8–16.
- MARTINI, R., BUTLER, A. M., JIANG, X.-M. and MURRAY, M., 1995, Pretranslational down regulation of cytochrome P450 2C11 in vitamin A-deficient male rat liver: Prevention by dietary inclusion of retinoic acid. Journal of Pharmacology and Experimental Therapeutics, 273, 427–434.
- MAYHEW, B. S., JONES, D. R. and HALL, S. D., 2000, An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition, 28, 1031–1037.
- MuNEIL, C. M. and MURRAY, M., 1996, Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites. Biochemical Pharmacology, 51, 15–20.
- MURRAY, M., 1988, Complexation of cytochrome P450 isozymes in hepatic microsomes from SKF-525-A-induced rats. Archives of Biochemistry and Biophysics, 262, 381–388.
- MURRAY, M., 1992, Metabolite intermediate complexation of microsomal cytochrome CYP 2C11 in male rat liver by nortriptyline. Molecular Pharmacology, 42, 931–938.
- MURRAY, M. and FIELD, S. L., 1992, Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants. Biochemical Pharmacology, 43, 2065–2071.
- MURRAY, M., SEFTON, R. M., MARTINI, R. and BUTLER, A. M., 1999, Comparative induction of CYP3A and CYP2B in rat liver by 3-benzoylpyridine and meyrapone. Chemico-Biological Interactions, 113, 161–173.
- MURRAY, M., WILKINSON, C. F., MARCUS, C. and DUBE, C. E., 1983, Structure—activity relationships in the interactions of alkoxymethylenedioxybenzene derivatives with rat hepatic microsomal mixed-function oxidases in vivo. Molecular Pharmacology, 24, 129–136.
- OMURA, T. and SATO, R., 1964, The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
- PERSHING, L. K. and FRANKLIN, M. R., 1982, Cytochrome P-450-metabolic-intermediate complex formation and induction by macrolide antibiotics: a new class of agents. Xenobiotica, 12, 687–699.
- PESSAYRE, D., LARREY, D., VITAUX, J., BREIL, P., BELGHITI, J. and BENHAMOU, J.-P., 1982, Formation of an inactive cytochrome P-450 Fe (II)-metabolite complex after administration of troleandomycin in humans. Biochemical Pharmacology, 31, 1699–1704.
- REIDY, G. F., MEHTA, I. and MURRAY, M., 1989, Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Molecular Pharmacology, 35, 736–743.
- REIN, H., RISTAU, 0., MISSELWITZ, R., BUDER, E. and RUCKPAUL, K., 1979, The importance of the spin equilibrium in cytochrome P-450 for the reduction rate of the heme iron. Acta Biologica et Medica Germanica, 38, 187–199.
- RING, B. J., BINKLEY, S. N., RosKos, L. and WRIGHTON, S. A., 1995, Effect of fiuoxetine, norfiuoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed f-hydroxy midazolam formation in vitro. Journal of Pharmacology and Experimental Therapeutics, 275, 1131–1135.
- ROOS, P. H., 1999. Common multiple interactions of tricyclic antidepressants and orphenadrine with liver microsomal cytochrome P450 enzymes of the rat. Xenobiotica, 29, 629–640.
- ROOS, P. H. and MAHNKE, A., 1996, Metabolite complex formation of orphenadrine with cytochrome P450. Biochemical Pharmacology, 52, 73–84.
- SUTTON, D., BUTLER, A. M., NADIN, L. and MURRAY, M., 1997, Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. Journal of Pharmacology and Experimental Therapeutics, 282, 294–300.
- TRIEU, L. and MURRAY, M., 2000, Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem. Xenobiotica, 30, 131–140.
- WAXMAN, D. J., Ko, A. and WALSH, C., 1983, Regioselectivity and stereoselectivity of androgen hydroxylations catalysed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. Journal of Biological Chemistry, 258, 11937–11947.
- YU, L.-S., WILKINSON, C. F. and ANDERS, M. W., 1980, Generation of carbon monoxide during the microsomal metabolism of methylenedioxyphenyl compounds. Biochemical Pharmacology, 29, 1113–1122.